U.S. markets open in 3 hours 18 minutes
  • S&P Futures

    3,797.50
    -19.25 (-0.50%)
     
  • Dow Futures

    31,131.00
    -105.00 (-0.34%)
     
  • Nasdaq Futures

    12,591.75
    -90.00 (-0.71%)
     
  • Russell 2000 Futures

    2,189.00
    -16.80 (-0.76%)
     
  • Crude Oil

    61.00
    -0.28 (-0.46%)
     
  • Gold

    1,713.30
    -2.50 (-0.15%)
     
  • Silver

    25.99
    -0.40 (-1.50%)
     
  • EUR/USD

    1.2047
    -0.0020 (-0.17%)
     
  • 10-Yr Bond

    1.4700
    0.0000 (0.00%)
     
  • Vix

    27.33
    +3.23 (+13.40%)
     
  • GBP/USD

    1.3930
    -0.0022 (-0.16%)
     
  • USD/JPY

    107.3300
    +0.3280 (+0.31%)
     
  • BTC-USD

    49,334.42
    -2,144.79 (-4.17%)
     
  • CMC Crypto 200

    989.26
    +2.05 (+0.21%)
     
  • FTSE 100

    6,606.15
    -69.32 (-1.04%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Corbus Pharmaceuticals: Q3 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.6% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share fell 34.37% year over year to ($0.43), which missed the estimate of ($0.42).

Revenue of $1,231,000 decreased by 52.47% from the same period last year, which missed the estimate of $2,310,000.

Outlook

Corbus Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 10, 2020

View more earnings on CRBP

Time: 08:30 AM

ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/crbp/mediaframe/41687/indexl.html

Technicals

Company's 52-week high was at $9.78

52-week low: $0.91

Price action over last quarter: down 81.85%

Company Description

Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.